Nouscom raises EUR 120 million in Series D co-led by M Ventures, Revelation Partners

PUBT · 2d ago
Nouscom raises EUR 120 million in Series D co-led by M Ventures, Revelation Partners
  • Nouscom closed an oversubscribed EUR 120 million (USD 135 million) Series D financing co-led by M Ventures and Revelation Partners.
  • The clinical-stage biotech develops next-generation immunotherapies focused on cancer interception.
  • New investors included Angelini Industries, the European Investment Bank and Neva SGR; all existing investors participated.
  • Proceeds will advance lead cancer immunotherapy NOUS-209 through a global, registration-enabling trial for cancer interception in Lynch syndrome carriers.
  • NOUS-209 has received FDA Fast Track designation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck Ventures BV published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.